BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BeBetter Med readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BeBetter Med's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06514027-2100@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:BEBT-109: Phase 2 readout est. (NCT06514027)
DESCRIPTION:BEBT-109\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study 
 of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon
  20 Insertion Mutations\nEstimated primary completion: June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bebt-109#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06514027
URL:https://assetmemo.bio/drug/bebt-109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676175-3395@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ifupinostat: Phase 2 readout est. (NCT07676175)
DESCRIPTION:Ifupinostat\, phase 2.\nStudy: A Study of BEBT-908 in Combinati
 on With Chemotherapy in Patients With Previously Untreated Peripheral T-Ce
 ll Lymphoma (PTCL)\nEstimated primary completion: 31 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ifupinostat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07676175
URL:https://assetmemo.bio/drug/ifupinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368608-557@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:BEBT-701: Phase 1/2 readout est. (NCT07368608)
DESCRIPTION:BEBT-701\, phase 1/2\, Hypertension.\nStudy: A Study of BEBT-70
 1 in Patients With Mild to Moderate Hypertension and Elevated Low-Density 
 Lipoprotein Cholesterol（LDL-C）\nEstimated primary completion: 30 Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bebt-701#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073686
 08
URL:https://assetmemo.bio/drug/bebt-701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792253-3395@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ifupinostat: Phase 3 readout est. (NCT06792253)
DESCRIPTION:Ifupinostat\, phase 3\, Relapsed/Refractory Diffuse Large B-Cel
 l Lymphoma.\nStudy: Study Comparing BEBT-908 Combined With R to SOC for th
 e Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ifupinostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06792253
URL:https://assetmemo.bio/drug/ifupinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544056-9086@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:BEBT-209: Phase 2/3 readout est. (NCT07544056)
DESCRIPTION:BEBT-209\, phase 2/3\, Breast Cancer.\nStudy: A Study of BEBT-2
 09 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Tripl
 e-Negative Breast Cancer\nEstimated primary completion: June 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bebt-209#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07544056
URL:https://assetmemo.bio/drug/bebt-209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
